Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep997 | Pituitary - Clinical | ECE2017

Localization of the catheters during Bilateral sampling of the inferior petrosal sinuses can impact diagnostic power?

Chiloiro Sabrina , Pedicelli Alessandro , Valente Iacopo , Tartaglione Tommaso , Bianchi Antonio , Giampietro Antonella , Bima Chiara , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , De Marinis Laura

Introduction: Bilateral sampling of the inferior petrosal sinuses (IPSS) is considerate actually the best diagnostic test for Cushing.Patients and methods: We retrospectively reviewed our series of patients undergone IPSS for Cushing disease and we compared the difference between central and peripheral ACTH gradient in basal condition and after CRH stimulation in cases of localization of the tip of the catheters inside the inferior petrosal sinus or at t...

ea0037gp.20.07 | Pituitary – Hypopituitarism | ECE2015

Outcome and prognosis of typical and atypical pituitary adenomas in a monocentric experience

Chiloiro Sabrina , Doglietto Francesco , Iacovazzo Donato , Giampietro Antonella , Di Nardo Francesco , de Waure Chiara , Lauriola Libero , Mangiola Annunziato , Anile Carmelo , Maira Giulio , De Marinis Laura , Bianchi Antonio

Background and objective: Atypical pituitary adenomas (APA), in 2004, were defined according to WHO classification, as those with Ki-67>3%, excessive p53 expression and increased mitotic activity and invasive behaviour. The real usefulness of this classification is still controversial, so we reviewed compared clinical and prognostic features in our typical and atypical pituitary adenomas.Patients and methods: We retrospectively reviewed 343 consecuti...

ea0032p874 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Factors Affecting Prognosis in a Series of Acromegalic Patients

Fusco Alessandra , Bianchi Antonio , Giampietro Antonella , Iacovazzo Donato , Lugli Francesca , Chiloiro Sabrina , Piacentini Serena , Tartaglione Linda , Doglietto Francesco , Anile Carmelo , Maira Giulio , De Marinis Laura

Introduction: The main goal in the treatment of acromegaly is achieving biochemical and tumor mass control. Therapeutic options include surgery, medical treatment and, in selected cases, radiotherapy. A GH receptor (GHR) variant that differs for the genomic retention or exclusion (d3GHR) of exon 3 is present in about 50% of general population and its presence is related to a greater sensitivity to GH.Materials and methods: We describe a series of 118 pat...

ea0056p751 | Neuroendocrinology | ECE2018

Efficacy and safety of a combinated pasireotide lar, pegvisomant and cabergoline treatment in four cases of aggressive somatotrophinomas

Bima Chiara , Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Piacentini Serena , Milardi Domenico , Tartaglione Tommaso , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , Marinis Laura De

Introduction: A significant number of GH-secreting pituitary adenomas show an aggressive behavior, therefore, when uncontrolled acromegaly persists, a pharmaceutical combination may improve biochemical control, with reduction of disease morbidity and mortality. We aimed to describe the clinical features of four patients successfully treated with a pharmacological combination of pasireotide LAR, pegvisomant and cabergoline.Case reports: Acromegaly was dia...

ea0056p875 | Pituitary - Clinical | ECE2018

Efficacy of pasireotide lar in first line somatostatin analogue resistant acromegaly patients: experience from a large and single centre Italian cohort

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Tartaglione Tommaso , Bima Chiara , Piacentini Serena , Mirra Federica , Donfrancesco Federico , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , De Marinis Laura

Introduction: Pasireotide Lar is a new generation long-acting somatostatin multireceptor ligand, approved for the treatment of first line somatostatin analogue resistant patients. We aimed to review Pasireotide Lar efficacy data, in our series of patients affected by aggressive acromegaly.Patients: A retrospective longitudinal study was conducted on patients with aggressive acromegaly, resistant to first-line somatostatin analogues (SSA) and on treatment...

ea0070aep662 | Pituitary and Neuroendocrinology | ECE2020

Predictors of response to medical therapy with pegvisomant and pasireotide lar in SRLs-resistant acromegaly

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Mirra Federica , Donfrancesco Federico , Maya Fleseriu Cara , Lauretti Liveraba , Anile Carmelo , Gessi Marco , Rindi Guido , Pontecorvi Alfredo , Fleseriu Maria , Giustina Andrea , De Marinis Laura

Background: Pegvisomant(PegV) and Pasireotide LAR(Pasi) are commonly used in acromegaly patients resistant to first-generation SRLs. Predictors of response to therapy with PegV and Pasi in this subset of patients are still unclear. These findings may be useful in choosing the most appropriate therapeutic option for the personalized treatment of patients affected by more aggressive disease. We aimed to identify individual predictors of responses.Methods: ...